Videos

Jessica MacIntyre, DNP, MBA, APRN, NP-C, AOCNP, discusses ways to standardize the process of referring patients to the Leukemia and Lymphoma Society.

Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, highlights how her unit leveraged an educational video to improve compliance with double verification for high-alert medications.

Eric Zack, DNP, RN, ACNP-BC, AOCN, BMTCN, describes disseminated intravascular coagulation and best nursing strategies to mitigate the severity of this condition.

Donna Catamero, ANP-BC, OCN, CCRC, outlines best management strategies for treating patients receiving teclistamab who experience cytokine release syndrome.

Hilda Haynes-Lewis, PhD, ANP-BC, AOCNP; and Rosaleen Bloom PhD, APRN, ACNS-BC, AOCNS, discuss the ways a cancer diagnosis can impair an individual’s ability to work normally.

Meghan K. Berkenstock, MD, discusses the growing need for strong collaboration between ophthalmologists and gynecologic oncology care teams.

Mary Katherine Montes de Oca, MD, discusses the potential benefit of cryocompression therapy in preventing peripheral neuropathy in patients with gynecologic cancers who are receiving chemotherapy.

Arash Rezazadeh Kalebasty, MD, discusses the rates of dose reduction and treatment discontinuation for patients with hormone-sensitive prostate cancer receiving combination therapy with darolutamide.

Michael S. Leapman, MD, MHS, highlights the need for clearer information regarding genomic testing for patients with prostate cancer.

Kristin M. Daly, MSN, ANP-BC, AOCNP, highlights the difference between somatic and germline variants.

Karyn A. Goodman, MD, MS, provides perspective on the potential advantages of stereotactic body radiation therapy in locally advanced pancreatic cancer.

Reanne Booker, MN, NP, highlights factors that make a patient a good candidate for palliative radiation.

Zev A. Wainberg, MD, discusses the implications of the findings from the phase 3 NAPOLI 3 trial for patients with metastatic pancreatic ductal adenocarcinoma.

Aaron T. Gerds, MD, MS, unpacks data seen with momelotinib for patients with anemic myelofibrosis.

Grace Choong, MD; and Matthew Goetz, MD, discuss the effect of omitting adjuvant endocrine therapy for patients with estrogen receptor–positive breast cancer who were treated with neoadjuvant chemotherapy.

Ranee Mehra, MD, discusses the link between PD-L1 expression and increased immunotherapy efficacy in head and neck squamous cell carcinoma, and what future treatment options may look like for patients in this space.

Manmeet Ahulwalia, MD, MBA, underscores how novel treatment approaches in oncology are proving effective in managing brain metastases.

Daniel J. Verina, DNP, RN, MSN, ACNP-BC, underscores how nurses can assess neurological toxicities in both the inpatient and outpatient setting.

Paula Anastasia, RN, MN, AOCN, underscores the value of genetic testing in personalizing treatment decisions in ovarian maintenance therapy.

Laura Wood discusses the successful integration of avelumab, erdafitinib, and enfortumab vedotin-ejfv into oncology nursing practice.

Sherry Adkins, MSN, ANP-C, discusses some key considerations in ensuring quality patient care after they have completed CAR T-cell therapy at a specialized center.

Beth Sandy, MSN, CRNP, discusses the application of 2 FDA approved drugs for patients with non–small cell lung cancer and an exon 20 insertion mutation.

Kelley A. Rone, DNP, RN, AGNP-c, discusses the advantages associated with immunotherapy in the treatment of patients with gastrointestinal cancers.

Gretchen McNally PhD, ANP-BC, AOCN, spotlights the value that naloxone training for oncology nurses and providers could have for patients who are at a high-risk of overdose.

Ilene Galinsky, BSN, MSN, ANP-C, underscores effective symptom management strategies when prescribing venetoclax to patients with acute myeloid leukemia.

Laura J. Zitella, MS, RN, ACNP-BC, AOCN, presents a case study of a patient receiving chemotherapy for osteosarcoma who begins experiencing shortness of breath.

Aliènne Salleroli, MS, BSN, RN, OCN, underscores the importance of open dialogue surrounding diversity, equity, and inclusion in oncology leadership.

Ilene Galinsky, BSN, MSN, ANP-C, senior leukemia protocol research nurse practitioner at Dana-Farber Cancer Institute, underscores key prescribing considerations with venetoclax.